Genetic polymorphisms significantly influence responses to warfarin and clopidogrel. Polymorphisms in the cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase genes change warfarin pharmacokinetics and pharmacodynamics, respectively. Because these polymorphisms influence warfarin dose requirements, they may primarily help determine therapeutic warfarin doses in patients who newly start on the drug. To assist in estimating therapeutic warfarin doses, the warfarin label provides a pharmacogenomic dosing table and various warfarin pharmacogenomic dosing algorithms are available. On the other hand, polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics. These polymorphisms may be useful to identify clopidogrel nonresponders who may benefit from taking an alternative antiplatelet agent such as prasugrel and ticagrelor. Although both drugs have pharmacogenomic tests available for clinical use, their clinical utilities have not been established and are currently being actively studied. In this review, clinical application of warfarin and clopidogrel pharmacogenomics will be focused. With the current level of evidence, potential patients who may get benefit from warfarin and clopidogrel pharmacogenomic testing will be discussed. In addition, the interpretation of the warfarin and clopidogrel test results and the current barriers to widespread use of warfarin and clopidogrel pharmacogenomic testing will be discussed.
HigashiMKVeenstraDLKondoLMAssociation between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–1698.
2.
KleinTEAltmanRBErikssonNEstimation of the warfarin dose with clinical and pharmacogenomic data. N Engl J Med. 2009;360(8):753–764.
3.
RiederMJReinerAPGageBFEffect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285–2293.
4.
GageBFEbyCJohnsonJAUse of pharmacogenomic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326–331.
AnsellJHirshJHylekEPharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):160S–198S.
WeiLLocusonCWTracyTS. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol. 2007;72(5):1280–1288.
9.
LindhJDHolmLAnderssonMLInfluence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009;65(4):365–375.
10.
MeckleyLMWittkowskyAKRiederMJAn analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost. 2008;100(2):229–239.
11.
PalaretiGLegnaniCGuazzalocaGRisks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005;129(1):72–78.
12.
VooraDEbyCLinderMWProspective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005;93:700–705.
13.
SandersonSEmeryJHigginsJ. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7(2):97–104.
14.
LinderMWLooneySAdamsJE 3rdWarfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14(3):227–232.
15.
WangDChenHMomaryKMRegulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008;112:1013–1021.
16.
WadeliusMChenLYDownesKCommon VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262–270.
17.
LimdiNAMcGwinGGoldsteinJAInfluence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83(2):312–321.
18.
SchwarzUIRitchieMDBradfordYGenetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999–1008.
19.
AndersonJLHorneBDStevensSMRandomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116(22):2563–2570.
20.
SconceEAKhanTIWynneHAThe impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329–2333.
21.
PeriniJAStruchinerCJSilva-AssuncaoEPharmacogenomics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther. 2008;84(6):722–728.
22.
CavallariLHLangaeeTYMomaryKMGenetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87(4):459–464.
KadafourMHaughRPosinMSurvey on warfarin pharmacogenomic testing among anticoagulation providers. Pharmacogenomics. 2009;10(11):1853–1860.
26.
GinsburgGSVooraD. The long and winding road to warfarin pharmacogenomic testing. J Am Coll Cardiol. 2010;55(25):2813–2815.
27.
MeckleyLMNeumannPJ. Personalized medicine: factors influencing reimbursement. Health Policy. 2009;94(2):91–100.
28.
EckmanMHRosandJGreenbergSMCost-effectiveness of using pharmacogenomic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73–83.
29.
YouJHTsuiKKWongRSPotential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther. 2009;86(5):540–547.
30.
MeckleyLMGudgeonJMAndersonJLA policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010;28:61–74.
EpsteinRSMoyerTPAubertREWarfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010;55:2804–2812.
33.
CaracoYBlotnickSMuszkatM. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83(3):460–470.
34.
HuangSWChenHSWangXQValidation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009;19(3):226–234.
SingerDEAlbersGWDalenJE. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):546S–192S.
37.
ShinJCaoD. Comparison of warfarin pharmacogenomic dosing algorithms in a racially diverse large cohort. Pharmacogenomics. 2011;12:125–134.
ThackerSMGriceGRMilliganPEDosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. J Thromb Haemost. 2008;6:1445–1449.
40.
LenziniPWadeliusMKimmelSIntegration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87:572–578.
41.
FinkelmanBSGageBFJohnsonJAGenetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011;57(5):612–618.
42.
ShinJKayserSR. Accuracy of the pharmacogenomic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy2011;31. In press.
43.
SchwartzJBKaneLMooreKFailure of pharmacogenomic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc. 2011. In press.
44.
RellingMVKleinTE. CPIC: clinical pharmacogenomics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89:464–467.
45.
WrightRSAndersonJL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:2022–2060.
46.
AntmanEMHandM, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210–247.
47.
AngiolilloDJFernandez-OrtizABernardoEVariability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516.
48.
SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375.
49.
MomaryKMDorschMPBatesER. Genetic causes of clopidogrel nonresponsiveness: which ones really count?Pharmacotherapy. 2010;30:265–274.
50.
de MoraisSMWilkinsonGRBlaisdellJThe major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419–15422.
51.
De MoraisSMWilkinsonGRBlaisdellJIdentification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594–598.
52.
SimSCRisingerCDahlMLA common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103–113.
53.
CombescureCFontanaPMalloukNClinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(5):923–933.
VarenhorstCJamesSErlingeDGenetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30(14):1744–1752.
56.
BreetNJvan WerkumJWBoumanHJComparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754–762.
57.
PriceMJBergerPBTeirsteinPSStandard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–1105.
58.
GurbelPABeckerRCMannKGPlatelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–1834.
59.
GurbelPAShuldinerARBlidenKPThe relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011;161:598–604.
60.
TrenkDHochholzerWFrommMFCytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925–1934.
61.
GiustiBGoriAMMarcucciRRelation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103:806–811.
62.
MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.
63.
SibbingDStegherrJLatzWCytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916–922.
64.
PareGMehtaSRYusufSEffects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–1714.
65.
SorichMJVitryAWardMBPrasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010;8:1678–1684.
66.
WallentinLJamesSStoreyRFEffect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328.
67.
SibbingDKochWGebhardDCytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512–518.
68.
ColletJPHulotJSPenaACytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309–317.
69.
ShuldinerARO'ConnellJRBlidenKPAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–857.
70.
MalekLAPrzyluskiJSpiewakMCytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology. 2010;117:81–87.
71.
TirochKASibbingDKochWProtective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160:506–512.
72.
YamamotoKHokimotoSChitoseTImpact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol2011;57:194–201.
73.
HarmszeAMvan WerkumJWTen BergJMCYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J. 2010;31:3046–3053.
74.
MegaJLSimonTColletJPReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–1830.
75.
AngiolilloDJFernandez-OrtizABernardoEPlatelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?J Invasive Cardiol. 2004;16:169–174.
76.
AngiolilloDJFernandez-OrtizABernardoEPlatelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430–2435.
77.
SofferDMoussaIHarjaiKJImpact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?Catheter Cardiovasc Interv. 2003;59(1):21–25.
78.
BarkerCMMurraySSTeirsteinPSPilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv. 2010;3:1001–1007.
79.
TantryUSBlidenKPWeiCFirst analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556–566.
80.
MaedaAAndoHAsaiTDifferential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther. 2011;89(2):229–233.
81.
ScottSASangkuhlKGardnerEEClinical pharmacogenomics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328–332.
